All In Biotech

Free tool

FAERS Monitor: Chemet

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 019998 or its brand name (Chemet, Succimer). Reports on generic versions are filed under their own applications.

Reports

71

Serious

35

49% of reports

Hospitalization

13

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use23
  • product availability issue9
  • arthralgia6
  • hypertension5
  • no adverse event5
  • weight increased5
  • condition aggravated4
  • dizziness4
  • skin striae4
  • abdominal pain upper3
  • arrhythmia3
  • asthenia3
  • atrial fibrillation3
  • back pain3
  • cushingoid3

Reports by year received

View as table
YearReports
20094
20111
20123
20141
201615
20177
20183
20192
20201
20215
202216
20234
20242
20253
20264

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,088 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
skin striaeSignal4798.8307.92,433
cushingoidSignal3277.191.5572
product availability issueSignal9117.163.6924
arrhythmiaSignal318.86.234
atrial fibrillationSignal39.13.014
no adverse eventSignal58.23.525
off label useSignal237.85.6135
hypertensionSignal57.03.020
weight increasedSignal56.62.819
abdominal pain upperSignal34.31.45
arthralgiaSignal64.32.012
condition aggravatedSignal43.91.56
back pain33.81.34
dizziness42.40.92
asthenia32.40.81

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.